Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney Damage

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 456 participants.

Also called NCT07876544

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 456 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07876544
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07876544. Randomized; double masking; primary purpose treatment. Start 2026-09-22 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney Damage
Acronym
SABER
Condition
Hypertension
Intervention (Drug)
Sitogilun Malate
Intervention (Drug)
Allisartan Isoproxil
Intervention (Drug)
Amlodipine besylate
Intervention (Drug)
Sitogilun Malate Placebo
Intervention (Drug)
Allisartan Isoproxil Placebo
Lead sponsor
Shanghai Jiao Tong University School of Medicine (class: other)

Record details

Record id
cardio:ct-nct07876544
Content hash
65e6fbb8f4fb8d3a5678cedd5eceddcb68f2f30385f89accc8747e1970ce9ec4